There are few fields of medicine in which the individualisation of medicines is more
important than in the area of oncology. Under‐dosing can have significant ramifications due …

The prerequisites for the successful implementation of therapeutic drug monitoring (TDM)
include high inter-subject variation, low inter-occasion variation, narrow therapeutic index …

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree
of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to …

Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow
therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic …

For a select number of drugs, proper management of patients includes monitoring serum or
plasma concentrations of the drugs and adjusting the doses accordingly–this practice is …

New oral targeted anticancer therapies are revolutionizing cancer treatment by transforming
previously deadly malignancies into chronically manageable conditions. Nevertheless, drug …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …

Background: Oral anticancer drugs show a high interpatient variability in pharmacokinetics
(PK), leading to large differences in drug exposure. For many of these drugs, exposure has …

Therapeutic drug monitoring (TDM) can be defined as the measurement of drug in biological
samples to individualise treatment by adapting drug dose to improve efficacy and/or reduce …

Cancer is a common cause of death, and improvements in treatment are desperately
needed. The high degree of variation in systemic exposure for a given dose and the …